


RealRate

PHARMACEUTICAL 2018

M BeiGene

BeiGene Ltd. Rank 64 of 349





PHARMACEUTICAL 2018



BeiGene Ltd. Rank 64 of 349



The relative strengths and weaknesses of BeiGene Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BeiGene Ltd. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 165% points. The greatest weakness of BeiGene Ltd. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 53%, being 331% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	913,497
Cost of Goods Sold	0
Intangible Assets	7,359
Liabilities, Current	149,988
Liabilities, Non-Current	212,260
Other Assets	63,055
Other Compr. Net Income	660
Other Expenses	7,459
Other Liabilities	0
Other Net Income	7,393
Property and Equipment	62,568
Research and Development	269,018
Revenues	238,387
Selling, General and Administrative Expense	62,602

Output Variable	Value in 1000 USD
Assets	1,046,479
Liabilities	362,248
Expenses	339,079
Stockholders Equity	684,231
Net Income	-93,299
Comprehensive Net Income	-92,969
Economic Capital Ratio	53%

